Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

This early-stage trial is testing whether adding two targeted drugs — pazopanib and temozolomide — to the standard radiation and chemotherapy treatment for newly diagnosed glioblastoma (the most aggressive brain tumor) is safe and effective. **You may be eligible if...** - You are between 18 and 70 years old - You have been recently diagnosed with glioblastoma (grade IV brain tumor), confirmed by lab testing - You have had surgery (partial or full removal) for the tumor - You are scheduled for standard radiation and chemotherapy - Your blood counts and organ function meet required levels - Your general health is adequate for treatment **You may NOT be eligible if...** - Your chemotherapy had to be interrupted due to low blood counts - You have had prior radiation to the brain - You have serious liver, heart, or kidney problems - You are on medications that interact with the study drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.